Monash IVF Group Ltd (MVF) AI Stock Analysis

• Market Cap: AU$266.90M
• Dividend Yield: 7.76%
• Average Volume (3M): 6.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 14.24%
• EPS Growth: -109.59%
• Country: AU
• Employees: 997
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.04
• Shares Outstanding: 389,634,830
• 10 Day Avg. Volume: 4,762,214
• 30 Day Avg. Volume: 6,430,443
• PEG Ratio: -3.09
• Price to Book (P/B): 2.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 16.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.10
• Price Target Upside: 61.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 52 Neutral
• Price Target: AU$0.50 ▼(-26.47%Downside)

The overall stock score of 51.5 reflects the mixed financial performance, bearish technical indicators, and challenging valuation metrics. The strong cash flow and high dividend yield provide some support, but profitability issues and negative market momentum weigh heavily on the overall assessment.

Monash IVF Group Ltd Business Overview & Revenue Model

Company Description

Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic and IVF treatment services. The company was incorporated in 2014 and is based in Richmond, Australia.

How the Company Makes Money

Monash IVF Group Ltd generates revenue primarily through its assisted reproductive services, with in vitro fertilization (IVF) being the core offering. The company also earns income from ancillary services such as genetic testing, fertility consultations, and diagnostic imaging. These services are typically provided through a network of clinics, which are staffed by specialized medical professionals. Monash IVF Group further benefits from partnerships with healthcare providers and insurance companies, which can facilitate patient referrals and payments. Additionally, the company's focus on research and innovation helps maintain its competitive edge in the market, thereby attracting more clients seeking advanced fertility solutions.

Monash IVF Group Ltd Financial Statement Overview

Summary

Monash IVF Group Ltd shows mixed financial health. Despite robust revenue growth and strong cash flow generation, the company faces profitability challenges with recent operational losses. Its balance sheet shows moderate leverage, which requires monitoring. The company needs to focus on improving operational efficiencies to turn revenue growth into sustainable profits.

Income Statement

The income statement shows cause for concern with a negative EBIT and net income for the most recent year, indicating operational losses. Revenue growth rate was strong at 19.4% compared to the previous year, but this has not translated into profit growth due to higher costs. Gross profit margin stands at 33.5%, down from previous years, indicating increased cost pressures.

Balance Sheet

The balance sheet reveals a stable equity base with stockholders' equity at 47.6% of total assets. However, the debt-to-equity ratio is relatively high at 0.56, suggesting moderate leverage. Return on equity has turned negative due to the net loss, which is a risk factor.

Cash Flow

Cash flow is a bright spot with a strong operating cash flow to net income ratio, indicating good cash generation relative to net income. Free cash flow grew significantly by 203.6% year-over-year, highlighting effective capital expenditure management. However, the net loss casts a shadow on future cash flow sustainability.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	269.91M	254.96M	213.59M	192.29M	183.60M	145.42M
Gross Profit	89.82M	85.50M	63.41M	57.22M	57.66M	38.37M
EBITDA	11.50M	13.03M	48.49M	45.69M	51.21M	32.84M
Net Income	-2.29M	-6.53M	21.84M	18.41M	25.15M	11.73M
Balance Sheet
Total Assets	507.70M	508.47M	421.89M	387.10M	356.17M	354.22M
Cash, Cash Equivalents and Short-Term Investments	7.50M	11.33M	8.01M	7.87M	8.76M	15.07M
Total Debt	159.39M	135.37M	100.04M	77.23M	45.99M	57.57M
Total Liabilities	253.47M	261.81M	146.82M	117.20M	87.73M	102.10M
Stockholders Equity	249.55M	241.91M	273.20M	267.92M	266.19M	249.81M
Cash Flow
Free Cash Flow	13.11M	30.85M	10.16M	19.51M	33.30M	19.04M
Operating Cash Flow	29.46M	52.52M	37.95M	31.28M	43.25M	26.54M
Investing Cash Flow	-31.36M	-38.80M	-40.51M	-15.16M	-11.21M	-9.26M
Financing Cash Flow	4.78M	-10.39M	2.68M	-17.02M	-38.35M	-6.46M

Monash IVF Group Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVF, the sentiment is Neutral. The current price of 0.68 is above the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.75, and below the 200-day MA of 1.06, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 47.34 is Neutral, neither overbought nor oversold. The STOCH value of 79.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:MVF.

Monash IVF Group Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	€4.82B	18.16	-49.50%	1.84%	13.92%	-2.48%
MVF	52 Neutral	AU$266.90M	―	-0.87%	7.76%	14.24%	-109.59%
PGZ		€315.36M	―	-4.46%	―	―	―
RMSYF		$5.42B	1,144.55	0.52%	2.00%	―	―
SHL	73 Outperform	AU$12.56B	22.96	6.86%	3.36%	10.15%	6.20%
IDX	53 Neutral	AU$953.42M	105.35	1.14%	1.98%	7.83%	―

Monash IVF Group Ltd Corporate Events

Monash IVF Addresses Late Lodgement of CEO Resignation Notice

Monash IVF Group Limited announced the late lodgement of an Appendix 3Z following the resignation of Michael Knaap as Chief Executive Officer and Managing Director. The company acknowledged the oversight and emphasized its commitment to compliance with ASX disclosure obligations, stating that it will implement further measures to prevent future occurrences.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Challenger Limited Ceases Substantial Holding in Monash IVF Group

Challenger Limited, along with its associated entities, has announced that it has ceased to be a substantial holder in Monash IVF Group Limited. This change in holding could potentially impact Monash IVF Group’s shareholder structure and influence its market dynamics, as Challenger Limited’s exit may alter investor perceptions and stakeholder interests.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Announces CEO Resignation and Interim Leadership

Monash IVF Group Ltd announced the resignation of CEO and Managing Director Michael Knaap, who has been with the company since 2019, leading it through significant growth and transformation. Malik Jainudeen, the current Chief Financial Officer and Company Secretary, has been appointed as Acting CEO, bringing over a decade of experience with the company and a strong background in financial and healthcare sectors.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Addresses Embryo Transfer Incident with Enhanced Safeguards

Monash IVF Group Limited announced an incident at its Clayton laboratory where an embryo was incorrectly transferred, prompting an internal investigation and an expanded independent review. The company is implementing additional verification processes to prevent future occurrences and has informed relevant regulators and insurers, while maintaining its profit guidance.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Revises FY2025 Profit Guidance Amid Challenging Market Conditions

Monash IVF Group Limited has revised its profit guidance for the fiscal year ending June 2025, now expecting an underlying NPAT of approximately $27.5 million, down from the previously anticipated $30.0 million to $31.0 million. This adjustment is due to softer market and operating conditions experienced in March and April 2025, although some recovery was noted in May. The company is also monitoring potential impacts from a recent incident in Brisbane, which could affect patient registrations and other operational metrics.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Addresses ASX Inquiry on Isolated Incident

Monash IVF Group Ltd responded to an ASX inquiry regarding an incident of human error, which they consider isolated and not materially affecting their financial performance for FY2025. The company has initiated an independent investigation to address the incident responsibly, and while the announcement was marked as market sensitive due to its financial commentary, MVF maintains that the information was not initially disclosed as it was not deemed obligatory under listing rules.

UniSuper Ceases Substantial Holding in Monash IVF Group

Monash IVF Group Limited has announced that UniSuper Limited, acting as trustee for UniSuper and UniSuper Management Pty Limited, has ceased to be a substantial holder in the company as of April 11, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market dynamics, as substantial holders often play a significant role in company decisions and stock performance.

Soul Patts Increases Stake in Monash IVF Group

Monash IVF Group Ltd, a company listed on the Australian Securities Exchange (ASX: MVF), has seen a change in the substantial holding by Washington H. Soul Pattinson and Company Limited (Soul Patts). Soul Patts has increased its voting power in Monash IVF Group from 6.28% to 9.69%, reflecting a significant acquisition of shares. This change in shareholding indicates a stronger influence by Soul Patts in the company’s decision-making process, potentially impacting the strategic direction and operations of Monash IVF Group.

Monash IVF Investigates Embryo Transfer Incident at Brisbane Clinic

Monash IVF Group Limited has confirmed an incident at its Brisbane clinic where an embryo was incorrectly transferred between patients, resulting in the birth of a child. The company is conducting an independent investigation led by Fiona McLeod AO SC to identify further safeguards and is committed to implementing all recommendations. Despite the incident, Monash IVF does not consider it material to its FY2025 financial performance and has informed relevant regulatory bodies and its insurers.

UniSuper Acquires Substantial Stake in Monash IVF Group

UniSuper Limited, as trustee for UniSuper and UniSuper Management Pty Limited, has become a substantial holder in Monash IVF Group Ltd, acquiring a 5.04% voting power through 19,626,468 ordinary shares. This acquisition signifies UniSuper’s strategic interest in Monash IVF, potentially impacting the company’s shareholder dynamics and market positioning.